Processing your request


please wait...

Case Page

 

Case Status:    ONGOING    
On or around 10/04/2019 (Ongoing date of last review)

Filing Date: April 12, 2019

According to the Complaint, Zogenix is a pharmaceutical company that develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is ZX008, which is also known commercially by its trademarked name “FINTEPLA.” FINTEPLA is a low-dose fenfluramine that is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Zogenix’s NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (ii) consequently, Zogenix’s NDA for FINTEPLA was unlikely to gain FDA approval; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 19, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on September 10.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: ZGNX
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: N.D. California
DOCKET #: 19-CV-01975
JUDGE: Hon. Richard Seeborg
DATE FILED: 04/12/2019
CLASS PERIOD START: 02/06/2019
CLASS PERIOD END: 04/08/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Pomerantz LLP (New York)
No Document Title Filing Date
COURT: N.D. California
DOCKET #: 19-CV-01975
JUDGE: Hon. Richard Seeborg
DATE FILED: 09/10/2019
CLASS PERIOD START: 02/06/2019
CLASS PERIOD END: 04/08/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Levi & Korsinsky (San Francisco)
    44 Montgomery Street, Suite 650, Levi & Korsinsky (San Francisco), CA 94104
    (415) 291-2420 (415) 484-1294 ·
No Document Title Filing Date
—Related District Court Filings Data is not available